Valuation: Acrux Limited

Market Cap 58.97L 41.1L 36.66L 34.16L 31.08L 58.53L 40Cr 4.13Cr 1.61Cr 20Cr 1.54Cr 1.51Cr 65Cr P/E 2025
-0.95x
P/E 2026 -8.4x
Enterprise Value 67.1L 46.76L 41.72L 38.86L 35.37L 66.6L 45Cr 4.7Cr 1.83Cr 23Cr 1.76Cr 1.72Cr 74Cr EV / Sales 2025
2.07x
EV / Sales 2026 1.08x
Free-Float
95.6%
Yield 2025 *
-
Yield 2026 -

Last Transcript: Acrux Limited

1 week+5.26%
Current month+11.11%
1 month-9.09%
3 months-16.67%
6 months-9.09%
Current year-33.33%
1 week 0.01
Extreme 0.009
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.13
10 years 0.01
Extreme 0.009
0.38
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 24/08/2026
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+5.26%-33.33%-75.61% 40.98L
+0.02%-3.52%+36.11%+111.11% 1,01900Cr
-1.21%-6.99%+34.08%+60.96% 62TCr
+1.12%-0.20%+13.62%+80.24% 46TCr
-3.30%-6.15%+56.45%+34.69% 36TCr
+0.93%-1.83%+21.65%+41.43% 33TCr
+0.12%-4.05%+10.70%+33.53% 27TCr
-0.89%-5.83%-7.00%+7.91% 24TCr
-0.01%-3.62%+35.28%+52.02% 22TCr
-0.08%-4.98%+28.34%+93.61% 18TCr
Average +0.19%-2.26%+19.59%+43.99% 36.97TCr
Weighted average by Cap. +0.44%-3.63%+28.50%+68.49%

Financials

2025 2026
Net sales 44.88L 31.28L 27.9L 26L 23.66L 44.55L 30Cr 3.14Cr 1.22Cr 15Cr 1.17Cr 1.15Cr 49Cr 65.81L 45.86L 40.92L 38.12L 34.69L 65.33L 44Cr 4.61Cr 1.79Cr 23Cr 1.72Cr 1.68Cr 72Cr
Net income -59.45L -41.43L -36.96L -34.43L -31.34L -59.01L -40Cr -4.16Cr -1.62Cr -20Cr -1.56Cr -1.52Cr -65Cr -6L -4L -4L -3L -3L -6L -4.05Cr -42.27L -16.45L -2.07Cr -15.8L -15.46L -6.65Cr
Net Debt 27.72L 19.32L 17.23L 16.06L 14.61L 27.52L 19Cr 1.94Cr 75.48L 9.5Cr 72.52L 70.96L 31Cr 8L 6L 5L 5L 4L 8L 5.46Cr 56.9L 22.14L 2.78Cr 21.27L 20.81L 8.95Cr
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
06/26/06 A$0.0100 0.00% 5,000
05/26/05 A$0.0100 0.00% 14,01,470
02/26/02 A$0.0100 0.00% 13,92,258
01/26/01 A$0.0100 +11.11% 10,907
30/26/30 A$0.009000 -5.26% 10,83,094

Annual profits - Rate of surprise